Picton Mahoney Asset Management’s Apogee Therapeutics APGE Stock Holding History

Picton Mahoney Asset Management’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21.9M	Buy	+165,000	New	+$14.9M	0.16%	121

Other funds holding APGE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mercer Global Advisors Denver, Colorado $80B AUM 26.12% 1-Year Est. Return

RCP

Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

MSE

MUFG Securities EMEA London, United Kingdom $9.53B AUM 52.96% 1-Year Est. Return

Picton Mahoney Asset Management's APGE Position: Q2 2026 in Review

Picton Mahoney Asset Management opened a new position in Apogee Therapeutics (APGE) in Q2 2026: 165,000 shares worth $21.9M. The stake represents 0.16% of the portfolio and ranks #121 among its holdings.

141 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Picton Mahoney Asset Management held 165,000 shares of Apogee Therapeutics worth $21.9M as of Q2 2026.
Apogee Therapeutics was a new Picton Mahoney Asset Management position in Q2 2026.
Apogee Therapeutics made up 0.16% of Picton Mahoney Asset Management's portfolio in Q2 2026, its #121 holding.
141 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Picton Mahoney Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.